Researchers at George Mason University have received $450,000 in funding from the National Institutes of Health to pursue new research into whether cannabinoids can help treat HIV-associated disorders.
A partner in the testing review says the findings provide further proof that consumers should only buy from reputable CBD brands.
Written by some of the country’s top drug science and policy researchers, the review puts forward a number of ‘next steps’ for the country to consider pursuing in order to better support prospective medical cannabis patients in the UK.
Compared with babies of mothers who had never used cannabis, infants of those who still consumed the drug after 15 weeks had lower mean values for birthweight, birth length, and head circumference.
The researchers aren’t sure exactly how those who used the concentrates could have such high THC levels without incurring greater intoxication, but they suspect a tolerance may have been built up.
Just under 400 people involved in the research say cannabis reduced the severity of their immediate PTSD symptoms by more than half.
A Hawaii News Now investigation found that many of the cartridges would be banned in other US states for failing to meet safety standards.
The new study compared the urine tests of cannabis consumers with their medical history, and found no association between the drug and the risk of having a stroke.